REAL-TIMI 63B

REAL-TIMI 63B is a Phase 2b randomized, blinded, placebo controlled study to evaluate the efficacy, safety, PK/pharmacodynamic, and immunogenicity of repeat doses of MEDI6012 in adult subjects presenting with acute STEMI (ST segment elevation myocardial infarction).

REAL-TIMI 63B

MAIN RESULTS:
Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B
Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment–Elevation Myocardial Infarction_ Results of REAL-TIMI 63B
Circulation. 2022 Sep 20;146(12):907-916.


PRESENTATIONS

Preliminary Results – Cardioprotection and Plaque Regression with MEDI6012 in Acute ST Elevation Myocardial Infarction – Primary Results of the Phase 2B REAL-TIMI 63B Randomized Clinical Trial (Bonaca, ACC 2021)

REAL on ClinicalTrials.gov

CONTACT US About REAL

Location 60 Fenwood Road, Suite 7022 / 350 Longwood Avenue, Office Level One, Boston, MA 02115 Phone 800.385.4444 E-mail TIMI@partners.org
%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close